GLOBAL ACINETOBACTER PNEUMONIA THERAPEUTICS MARKET SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2023 - 2030)

Global Acinetobacter Pneumonia Therapeutics Market, By Drug Class (Cephalosporins, Carbapenems, Aminoglycosides, Polymyxins), By Route of Administration (Oral, Intravenous, Others), By Geography (North America, Europe, Asia Pacific, Latin America, Middle East and Africa)

Global Acinetobacter Pneumonia Therapeutics Market- Recent Developments

Business Development Activities by the Market Players

On May 23, 2023, the U.S. Food and Drug Administration approved Xacduro (sulbactam for injection; durlobactam for injection), a new treatment for hospital-acquired bacterial pneumonia (HABP) and ventilator-associated bacterial pneumonia (VABP) caused by susceptible strains of bacteria called Acinetobacter baumannii-calcoaceticus complex, for patients 18 years of age and older
On April 17, 2023, Innoviva, Inc., a diversified holding company with a portfolio of royalties and other healthcare assets, announced that the U.S. Food and Drug Administration’s (FDA) Antimicrobial Drugs Advisory Committee (AMDAC) unanimously voted 12-0 in support of approval based on a favorable benefit-risk assessment of sulbactam-durlobactam for the treatment of adults with hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia caused by susceptible strains of Acinetobacter baumannii-calcoaceticus complex (Acinetobacter)